Literature DB >> 24571540

Expression of HMGA2 in bladder cancer and its association with epithelial-to-mesenchymal transition.

X Ding1, Y Wang, X Ma, H Guo, X Yan, Q Chi, J Li, Y Hou, C Wang.   

Abstract

OBJECTIVES: High mobility group protein2 (HMGA2) and epithelial-to-mesenchymal transition are both related to progress of bladder cancer, however, the relationship between HMGA2, E-cadherin and vimentin in bladder cancer is not yet known. Thus, this study has examined expression of HMGA2, E-cadherin and vimentin in bladder cancer and investigated their relationship.
MATERIALS AND METHODS: The 5637 bladder cancer cell line and SV-HUC-1 normal uroepithelial cells were used to study expression of HMGA2, E-cadherin and vimentin using RT-PCR and western blotting. Paraffin wax-embedded bladder cancer tissues were used to study protein expression using immunohistochemistry and χ(2) analysis and Kendall's correlation were utilized statistical methods.
RESULTS: Overexpression of HMGA2 was associated with down-regulation of E-cadherin and up-regulation of vimentin in the 5637 bladder cancer line. A total of 49 paraffin wax-embedded tissues of transitional cell bladder cancer were used. Positive expression levels of HMGA2 protein and vimentin were 41 and 43% in bladder tissues, respectively. No expression of E-cadherin was found in 43%. Expression of HMGA2, loss of E-cadherin and expression of vimentin are all significantly correlated with bladder cancer grade and stage. Loss of E-cadherin and expression of vimentin both correlated with recurrence of the bladder cancer.
CONCLUSIONS: Expression of HMGA2 was closely associated with occurrence of epithelial-to-mesenchymal transition. Expression of HMGA2, loss of E-cadherin and expression of vimentin may indicate high degree malignancy of bladder cancer. Loss of E-cadherin expression and positive expression of vimentin may predict recurrence of bladder cancer.
© 2014 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24571540      PMCID: PMC6496012          DOI: 10.1111/cpr.12096

Source DB:  PubMed          Journal:  Cell Prolif        ISSN: 0960-7722            Impact factor:   6.831


  22 in total

Review 1.  HMGA2: A pituitary tumour subtype-specific oncogene?

Authors:  Monica Fedele; Dario Palmieri; Alfredo Fusco
Journal:  Mol Cell Endocrinol       Date:  2010-03-27       Impact factor: 4.102

2.  HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases.

Authors:  Thea Eline Hetland; Arild Holth; Janne Kærn; Vivi Ann Flørenes; Claes G Tropé; Ben Davidson
Journal:  Virchows Arch       Date:  2012-04-04       Impact factor: 4.064

3.  Prognostic role of E-cadherin and Vimentin expression in various subtypes of soft tissue leiomyosarcomas.

Authors:  Wei Tian; Guowen Wang; Jilong Yang; Yi Pan; Yulin Ma
Journal:  Med Oncol       Date:  2013-01-05       Impact factor: 3.064

Review 4.  The epithelial-mesenchymal transition (EMT) and colorectal cancer progression.

Authors:  Richard C Bates; Arthur M Mercurio
Journal:  Cancer Biol Ther       Date:  2005-04-04       Impact factor: 4.742

Review 5.  Epithelial plasticity, cancer stem cells, and the tumor-supportive stroma in bladder carcinoma.

Authors:  Geertje van der Horst; Lieke Bos; Gabri van der Pluijm
Journal:  Mol Cancer Res       Date:  2012-06-19       Impact factor: 5.852

6.  HMGA2 is a driver of tumor metastasis.

Authors:  Asahiro Morishita; M Raza Zaidi; Akira Mitoro; Devipriya Sankarasharma; Matthias Szabolcs; Yasunori Okada; Jeanine D'Armiento; Kiran Chada
Journal:  Cancer Res       Date:  2013-05-30       Impact factor: 12.701

7.  HMGA2 elicits EMT by activating the Wnt/β-catenin pathway in gastric cancer.

Authors:  Lang Zha; Jing Zhang; Weixue Tang; Neng Zhang; Miao He; Yi Guo; Ziwei Wang
Journal:  Dig Dis Sci       Date:  2012-11-08       Impact factor: 3.199

8.  Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer.

Authors:  Fariz Nurwidya; Fumiyuki Takahashi; Akiko Murakami; Kazuhisa Takahashi
Journal:  Cancer Res Treat       Date:  2012-09-30       Impact factor: 4.679

9.  WNT10B/β-catenin signalling induces HMGA2 and proliferation in metastatic triple-negative breast cancer.

Authors:  Peter Wend; Stephanie Runke; Korinna Wend; Brenda Anchondo; Maria Yesayan; Meghan Jardon; Natalie Hardie; Christoph Loddenkemper; Ilya Ulasov; Maciej S Lesniak; Rebecca Wolsky; Laurent A Bentolila; Stephen G Grant; David Elashoff; Stephan Lehr; Jean J Latimer; Shikha Bose; Husain Sattar; Susan A Krum; Gustavo A Miranda-Carboni
Journal:  EMBO Mol Med       Date:  2013-01-11       Impact factor: 12.137

10.  MicroRNA-23b functions as a tumor suppressor by regulating Zeb1 in bladder cancer.

Authors:  Shahana Majid; Altaf A Dar; Sharanjot Saini; Guoren Deng; Inik Chang; Kirsten Greene; Yuichiro Tanaka; Rajvir Dahiya; Soichiro Yamamura
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240

View more
  22 in total

1.  HMGA2 regulates CD44 expression to promote gastric cancer cell motility and sphere formation.

Authors:  Junying Sun; Baocun Sun; Dongwang Zhu; Xiulan Zhao; Yanhui Zhang; Xueyi Dong; Na Che; Jing Li; Fang Liu; Nan Zhao; Danfang Zhang; Tieju Liu; Xian Lin
Journal:  Am J Cancer Res       Date:  2017-02-01       Impact factor: 6.166

2.  Silencing of HMGA2 suppresses cellular proliferation, migration, invasion, and epithelial-mesenchymal transition in bladder cancer.

Authors:  Zhan Shi; Xiang Li; Ding Wu; Run Tang; Renfu Chen; Song Xue; Xiaoqing Sun
Journal:  Tumour Biol       Date:  2015-12-18

3.  High-mobility group A2 overexpression is an unfavorable prognostic biomarker for nasopharyngeal carcinoma patients.

Authors:  Zhuoxing Liu; Kunpeng Wu; Zhixiong Yang; Aibing Wu
Journal:  Mol Cell Biochem       Date:  2015-07-17       Impact factor: 3.396

4.  Downregulation of HMGA2 by Small Interfering RNA Affects the Survival, Migration, and Apoptosis of Prostate Cancer Cell Line.

Authors:  Shima Khajouee; Elham Baghbani; Ali Mohammadi; Behzad Mansoori; Dariush Shanehbandi; Khalil Hajiasgharzadeh; Behzad Baradaran
Journal:  Adv Pharm Bull       Date:  2021-04-03

Review 5.  SMAD7: a timer of tumor progression targeting TGF-β signaling.

Authors:  Lingyu Luo; Nianshuang Li; Nonghua Lv; Deqiang Huang
Journal:  Tumour Biol       Date:  2014-06-17

6.  Downregulation of HMGA2 inhibits cellular proliferation and invasion, improves cellular apoptosis in prostate cancer.

Authors:  Junyan Cai; Guangyu Shen; Su Liu; Qingbing Meng
Journal:  Tumour Biol       Date:  2015-08-05

7.  Breast cancer cells promote a notch-dependent mesenchymal phenotype in endothelial cells participating to a pro-tumoral niche.

Authors:  Pegah Ghiabi; Jie Jiang; Jennifer Pasquier; Mahtab Maleki; Nadine Abu-Kaoud; Najeeb Halabi; Bella S Guerrouahen; Shahin Rafii; Arash Rafii
Journal:  J Transl Med       Date:  2015-01-27       Impact factor: 5.531

8.  HMGA2 is associated with epithelial-mesenchymal transition and can predict poor prognosis in nasopharyngeal carcinoma.

Authors:  You-You Xia; Li Yin; Hao Tian; Wen-Jie Guo; Ning Jiang; Xue-Song Jiang; Jing Wu; Meng Chen; Jian-Zhong Wu; Xia He
Journal:  Onco Targets Ther       Date:  2015-01-17       Impact factor: 4.147

9.  Identification of genomic alterations in pancreatic cancer using array-based comparative genomic hybridization.

Authors:  Jian-Wei Liang; Zhi-Zhou Shi; Tian-Yun Shen; Xu Che; Zheng Wang; Su-Sheng Shi; Xin Xu; Yan Cai; Ping Zhao; Cheng-Feng Wang; Zhi-Xiang Zhou; Ming-Rong Wang
Journal:  PLoS One       Date:  2014-12-11       Impact factor: 3.240

10.  HMGA2 expression distinguishes between different types of postpubertal testicular germ cell tumour.

Authors:  Lars Kloth; Andrea Gottlieb; Burkhard Helmke; Werner Wosniok; Thomas Löning; Käte Burchardt; Gazanfer Belge; Kathrin Günther; Jörn Bullerdiek
Journal:  J Pathol Clin Res       Date:  2015-09-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.